Biotech & Biomed Execution for R&D, GMP, and Clinical Translation
We help founders, boards and hospital groups turn science into regulated products and programs: lab build-outs, QMS/GMP, clinical development, and BD & partnerships across APAC & Europe.
Current: Co-founder & CSO (Velantis Therapeutics) and CSO (Miskawaan Health Group)
Former: Senior Director (Celligenics) and COO (Austrianova / SG Austria)
What We Do
Focused, senior execution you can deploy immediately.
R&D & Clinical Translation
Program strategy, protocol pathways, Phase I/II design support, KOL/CRO alignment, and clinical operations readiness.
GMP/QMS & Tech Transfer
Build or upgrade QMS/QA/QC, supplier qualification, pilot-to-GMP scale-up, documentation suites, and validation.
Lab Build-Outs & Operations
Value proposition, equipment specs, layout/flows, method validation, hiring, and operations playbooks.
Advanced Biologics & Regenerative
Cell therapy, secretome, exosomes, and probiotics; manufacturing partners and regulatory road-mapping.
Business Development & Partnerships
Corporate BD, licensing & co-development, investor materials, diligence, and deal support.
Interim Leadership
Hands-on COO/CSO-level execution to de-risk timelines, budgets, and stakeholder alignment.
Selected Engagements & Outcomes
- Clinical trials management — Enabled commercialization steps, QMS support, co-authored publications.
- Regenerative medicine program — Enabled commercialization steps, QMS support, co-authored publications.
- Clinical network CSO — Executive Committee, gateway for advanced therapeutics, Head of Procurement, clinical rollout.
- Cell therapy manufacturing — GMP process/device work; two oncology trials completed.
Why Anovasia
25+ years from bench to bedside; 30+ publications, 7 core inventions; APAC-EU network. Blend of science leadership + operations + BD—focused on outcomes, not slideware.
Team
Principal
Hands-on
John A. Dangerfield, PhD — Current: Co-founder & CSO, Velantis Therapeutics, leading clinical development, fundraising and operations; and CSO, Miskawaan Health Group.
Former: Senior Director (Celligenics) and COO (Austrianova / SG Austria). Specialist in cell & gene therapy, regenerative medicine, clinical development, and GMP/QMS.
Capabilities snapshot
- GMP/QMS set-up & audits
- Clinical ops & CRO/KOL alignment
- Tech transfer & scale-up
- Commercial & BD support
- Fluent in German language
- Investment & grants
Associate · Medical Liaison
Dr Arkar Win Maung, MBBS
Medical doctor working across clinical operations, quality management and the development of new therapies. Supports Anovasia engagements on clinical programme design, regulatory coordination, CRO oversight and clinical documentation and case reporting. Previously Senior Product Specialist at Pfizer (DKSH Myanmar) and Product Specialist in CTC/NGS diagnostics; Master of Healthcare and Wellness Management candidate at Mahidol University. Co-author of the 2026 Bioengineering chronic-wound case report.
Recent Publications & Media
Recent peer-reviewed work and public commentary.
Cell-Free Wharton's Jelly-Derived MSC Secretome in a Polymeric Carrier for Refractory Chronic Wounds: Two Cases
Two chronic wounds, open for one to two years and unresponsive to standard and advanced care, closed completely with a cell-free MSC secretome delivered in a thermoresponsive carrier. Dangerfield, Maung & Klinoubol. Bioengineering 13(9):1077.
Read on PubMed →
Emergence of Cell and Gene Therapy Community in Singapore
Commentary on commercialising cell and gene therapy in Southeast Asia: Singapore's growing CGT start-up base, and the funding, regulatory and clinical-trial cost hurdles investors and government need to address.
Development and Functional Testing of a Novel In Vitro Delayed Scratch Closure Assay
First description of a chronic wound in vitro model using pro-inflammatory stimulation, validated with Wharton's jelly MSC secretome. Aw, Chen, Yeo, Dangerfield & Mok. Histochemistry and Cell Biology, Vol. 162.
Extracellular Vesicles and Their Membranes: Exosomes vs. Virus-Related Particles
Comparative analysis of exosome and virus-related particle biology and membrane properties. Cortes-Galvez, Dangerfield & Metzner. Membranes 13(4):397. PMID: 37103824.
Contact
Email: john@anovasia.com | LinkedIn: /john-a-dangerfield
Prefer a quick form? Drop a note below—I'll reply within one business day.